Recombinant adeno-associated viral (rAAV) vectors based on serotype 2 are currently being
evaluated most extensively in animals and human clinical trials. rAAV vectors constructed …

Adeno-associated viruses (AAVs) are single-stranded dependent parvoviruses being
developed as transducing vectors. Although at least five serotypes exist (AAV types 1 to 5 …

Although most animal experiments with recombinant adeno-associated virus (AAV) vectors
have been based on AAV serotype 2, recent studies showed that AAV vectors based on AAV …

Recombinant adeno-associated virus (rAAV) vectors are unique among the vector classes
currently available for human gene therapy in that they are based upon a class of viruses …

Standard protocols for the generation of adenoassociated virus type 2 (AAV-2)-based
vectors for human gene therapy applications require cotransfection of cells with a …

Gene transfer vectors based on the human adeno-associated virus serotype 2 (AAV-2) have
been developed and tested in pre-clinical studies for almost 20 years, and are currently …

Vectors derived from adeno-associated virus serotype 2 (AAV-2) represent a most promising
tool for human gene transfer because these vectors are neither pathogenic nor toxic to the …

The use of recombinant adeno-associated viral vectors (rAAVs) as gene transfer tools has
increased dramatically during the past several years, establishing AAV as the vector of …

Vectors based on adeno-associated virus (AAV) are the subject of increasing interest as
research tools and agents for in vivo gene therapy. A current limitation on the technology is …

Recombinant adeno-associated viral (AAV) vectors have rapidly advanced to the forefront of
gene therapy in the past decade. The exponential progress of AAV-based vectors has been …